Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in kidney cancer
- Trial result
Kidney cancer
Tobemstomig (PD-1×LAG-3) ± tiragolumab (anti-TIGIT) + axitinib adds toxicity without PFS/ORR gain in 1L ccRCC
Tobemstomig is a bispecific PD-1/LAG-3 checkpoint inhibitor evaluated with axitinib (VEGF-TKI), with or without tiragolumab (anti-TIGIT), versus pembrolizumab (anti–PD-1) + axitinib in this randomized, open-label…
NCT05805501 - New trial
Kidney cancer
Phase 1 BMS-986527 allogeneic CD70 CAR T-cell therapy is tested alone or with nivolumab or cabozantinib in clear cell RCC
This Phase 1, multicenter, open-label study from Juno Therapeutics, a Bristol Myers Squibb company, evaluates BMS-986527, a healthy-donor-derived, allogeneic CD70-targeted CAR T-cell therapy in unresectable or…
NCT07848295 First-in-human - Trial result
Kidney cancer
Improving HRQoL Correlates With Longer PFS/OS in LITESPARK-005
Belzutifan is an oral hypoxia-inducible factor-2α (HIF-2α) inhibitor compared with everolimus (mTOR inhibitor) in the randomized Phase 3 LITESPARK-005 trial (NCT04195750) in previously treated advanced clear cell RCC…
NCT04195750 - Trial result
Kidney cancer
Tivozanib (VEGFR TKI) Beats Tivozanib+nivolumab in post-ICI mRCC, extending 2L PFS
Tivozanib is an oral VEGFR-1/2/3 tyrosine kinase inhibitor (TKI); TiNivo-2 randomized post–immune checkpoint inhibitor (ICI) metastatic RCC patients to standard-dose tivozanib 1.34mg (21/28 days) vs reduced-dose…
NCT04987203 - Trial result
Kidney cancer
Casdatifan (HIF-2α inhibitor) Monotherapy in Late-Line ccRCC Shows Class-On-Target Anemia/Hypoxia With Low Discontinuation
Casdatifan is a potent, selective oral hypoxia-inducible factor-2α (HIF-2α) inhibitor evaluated as monotherapy in the ongoing ARC-20 platform study (NCT05536141) in metastatic clear cell RCC previously treated with…
NCT05536141 - New trial
Kidney cancer
Phase 2 Elekta Unity MR-linac MR-guided SBRT (MRgRT) for localized renal cell carcinoma
NYU Langone Health is running this single-arm Phase 2 study testing whether MRI-guided, online-adaptive stereotactic body radiation therapy (SBRT) delivered on the Elekta Unity MR-guided linear accelerator can…
NCT07767500 Exploratory - Trial result
Kidney cancer
FTI Darlifarnib + Cabozantinib Shows 33–50% ORR in Pretreated ccRCC
Darlifarnib (KO-2806) is an investigational farnesyl transferase inhibitor that blocks RHEB farnesylation to selectively suppress mTORC1, here combined with cabozantinib in the Phase 1a/b FIT-001 trial (NCT06026410).…
NCT06026410 - New trial
Kidney cancer
Phase 1 cabozantinib multi-kinase (MET/AXL/VEGFR2) inhibitor + nivolumab PD-1 mAb
MD Anderson’s Phase 1 proof-of-concept study tests whether cabozantinib plus nivolumab reshapes the *bone* immune microenvironment in clear cell renal cell carcinoma (ccRCC) with bone metastases, using paired…
NCT07187869 Exploratory - New trial Spotlight
Kidney cancer
Phase 3 belzutifan HIF-2α inhibitor + zanzalintinib multi-kinase VEGFR/c-MET inhibitor in advanced RCC.
Merck Sharp & Dohme (MSD) is running LITESPARK-034 (MK-6482-034), a Phase 3 randomized, double-blind study testing belzutifan plus zanzalintinib versus belzutifan plus placebo in advanced/unresectable renal cell…
NCT07489495 Registrational - New trial
Kidney cancer
Phase 1/2 mercaptopurine (6‑MP) purine antagonist (DNA synthesis inhibitor) in HLRCC
This Phase 1/2, open-label, multi-cohort study evaluates oral mercaptopurine (6‑MP), a thiopurine antimetabolite/purine antagonist that disrupts DNA/RNA synthesis after intracellular activation, to define safety,…
NCT07716735 Exploratory - New trial
Kidney cancer
Phase 1 casdatifan selective HIF-2α transcription-factor inhibitor pilot in refractory ccRCC
Vanderbilt-Ingram Cancer Center is running a single-institution, open-label pilot study of oral casdatifan (AB521), a small-molecule, allosteric inhibitor of HIF-2α–dependent transcription, in metastatic clear cell…
NCT07748988 Exploratory - Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + nivolumab/ipilimumab extends PFS—but no OS gain—in 1L advanced ccRCC (COSMIC-313)
Cabozantinib, a multi-kinase TKI targeting VEGFR/MET/AXL, was added to nivolumab (PD-1) + ipilimumab (CTLA-4) in the double-blind Phase III COSMIC-313 trial (NCT03937219) in previously untreated advanced clear cell…
NCT03937219 - Trial result
Kidney cancer
Belzutifan (HIF-2α inhibitor) + Lenvatinib (VEGFR TKI) Extends PFS vs Cabozantinib in Post–PD-(L)1 ccRCC (LITESPARK-011)
Belzutifan is an oral HIF-2α inhibitor and lenvatinib is an oral multikinase VEGFR TKI; this open-label Phase 3 trial (LITESPARK-011; NCT04586231) randomized previously treated advanced clear-cell RCC after…
NCT04586231 - Trial result Spotlight
Kidney cancer
Panitumumab-based EGFR blockade drives 53.9% ORR in platinum-refractory renal medullary carcinoma
SMARCB1-deficient renal medullary carcinoma (RMC)—a rare, hypoxic medullary kidney cancer enriched in young patients of African descent with sickle cell trait—was historically treated with platinum-based chemotherapy…
NCT06444880 - Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + Radium-223 (bone-seeking α-emitter) fails to extend SSE-free survival in mRCC bone mets (RADICAL)
Radium-223 dichloride is an osteotropic alpha-particle radiopharmaceutical, combined here with cabozantinib, an oral multikinase TKI (VEGFR2/MET/AXL) with known activity in RCC bone disease; RADICAL (Alliance…
NCT04071223 - Trial result Spotlight
Kidney cancer
Pembrolizumab + belzutifan (HIF-2α) improves adjuvant DFS in high-risk ccRCC—at a clear G3+ toxicity cost
Pembrolizumab is a PD-1 antibody and belzutifan is an oral hypoxia-inducible factor-2α (HIF-2α) inhibitor; in LITESPARK-022 (Phase 3, double-blind; NCT05239728), patients with resected clear-cell RCC at increased…
NCT05239728 - Trial result
Kidney cancer
OMNIVORE supports nivolumab stop-early responders, not salvage ipilimumab
Nivolumab is a PD-1 checkpoint inhibitor, and ipilimumab is a CTLA-4 checkpoint inhibitor; OMNIVORE tested response-adapted immunotherapy in advanced RCC (Phase 2; NCT03203473). Among 83 patients, early nivolumab…
NCT03203473 - Trial result
Kidney cancer
Casdatifan (HIF-2α inhibitor) drives 31–35% ORR with ~12.2-mo PFS in refractory metastatic ccRCC
Casdatifan is an orally bioavailable, potent and selective small-molecule HIF-2α inhibitor evaluated as monotherapy in the ARC-20 dose-expansion study (NCT05536141) in refractory metastatic clear cell renal cell…
NCT05536141 - Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + nivolumab (PD-1) sustains PFS/OS gains vs sunitinib in aRCC with liver metastases
Cabozantinib is a multikinase VEGFR/MET/AXL inhibitor paired here with nivolumab, a PD-1 checkpoint inhibitor; this exploratory CheckMate-9ER (Phase 3; NCT03141177) subgroup analysis evaluated first-line clear-cell…
NCT03141177 - Trial result
Kidney cancer
HC-7366 (GCN2 activator; ISR/metabolic-stress agonism) + belzutifan (HIF-2α inhibitor) posts 37% BORR in post–PD-(L)1/VEGF-TKI ccRCC
HC-7366 is an oral, selective activator of GCN2 kinase designed to drive the integrated stress response and suppress HIF/cell-cycle programs; belzutifan is an oral HIF-2α inhibitor. In this Phase 1b open-label…
- New trial Spotlight
Kidney cancer
Phase 3 MO-03 live biotherapeutic (butyrate‑producing Clostridium butyricum ) added to PD‑1/CTLA‑4±VEGFR TKI first-line ccRCC
This SWOG Cancer Research Network Phase 3 double-blind, placebo-controlled trial (BioFront; also listed as SWOG S2419) tests whether MO-03—a live biotherapeutic containing a butyrate‑producing bacterium *Clostridium…
NCT07383441 Registrational - Trial result Spotlight
Kidney cancer
Pembrolizumab (PD-1) + high-dose IL-2 (T-cell–activating cytokine) drives 42% CRs and >84-mo OS in 1L ccRCC
Pembrolizumab (anti–PD-1) combined with high-dose interleukin-2 (aldesleukin; pleiotropic T-cell/NK-cell activating cytokine) was evaluated as a fixed-duration, single-arm Phase 2 regimen in treatment-naive advanced…
NCT02964078 - Trial result Spotlight
Kidney cancer
CaboNivo (cabozantinib VEGFR/MET/AXL TKI + nivolumab PD-1) drives 43% ORR in metastatic non–clear cell RCC—chromophobe remains refractory
Cabozantinib (a multikinase VEGFR/MET/AXL inhibitor) plus nivolumab (PD-1 antibody) was evaluated in an investigator-initiated Phase 2 study in advanced/metastatic non–clear cell RCC with 0–1 prior systemic therapies…
NCT03635892 - Trial result Spotlight
Kidney cancer
CBM588 (Clostridium butyricum live biotherapeutic) + ICB combos drives big PFS/ORR gains in dysbiotic 1L mRCC
CBM588 is an oral *Clostridium butyricum*–based live biotherapeutic intended to modulate the gut microbiome; here it was added to standard first-line immune checkpoint–based regimens (nivolumab/ipilimumab or…
NCT03829111 - Trial result
Kidney cancer
Sunitinib (VEGFR TKI) Response in mccRCC Tracks with Pro-inflammatory TME; DSP Signature Predicts Benefit
Sunitinib is an oral VEGFR/PDGFR/KIT tyrosine kinase inhibitor; in this Phase 2 single-arm trial in metastatic clear cell RCC treated peri-cytoreductive nephrectomy (NCT00715442), 46 patients underwent spatial…
NCT00715442 - Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + nivolumab (PD-1) doubles PFS in aRCC with baseline bone metastases vs sunitinib
Cabozantinib plus nivolumab (C+N) combines multi-kinase VEGFR/MET/AXL inhibition with PD-1 blockade and was compared with sunitinib in the Phase 3 CheckMate-9ER first-line clear-cell aRCC trial (NCT03141177; N=651);…
NCT03141177 - Trial result
Kidney cancer
AI-quantified high-branching tumor vasculature (H&E) stratifies recurrence risk beyond TNM in adjuvant RCC
In a post-hoc biomarker analysis of CheckMate 914 (CM914; NCT03138512), an adjuvant randomized Phase 3 trial after nephrectomy in localized/high-risk RCC, investigators used a deep-learning model on H&E whole-slide…
NCT03138512 - Trial result
Kidney cancer
Radium-223 (bone-seeking alpha emitter) + cabozantinib (VEGFR/MET/AXL TKI) misses SSE-free survival in RCC bone metastases
Radium-223 dichloride is a bone-targeted alpha-emitting radiopharmaceutical, and cabozantinib is a multikinase VEGFR/MET/AXL inhibitor with known activity in RCC bone disease; RADICAL (Alliance A031801; NCT04071223)…
NCT04071223 - Trial result
Kidney cancer
Belzutifan (HIF-2α inhibitor) + lenvatinib holds HRQoL steady vs cabozantinib in post–PD-(L)1 RCC
Belzutifan (a first-in-class oral HIF-2α inhibitor) plus lenvatinib (a VEGFR/FGFR multikinase TKI) was compared with cabozantinib (VEGFR/MET/AXL TKI) in the open-label Phase 3 LITESPARK-011 trial (NCT04586231) in…
NCT04586231 - Trial result
Kidney cancer
Tivozanib (VEGFR TKI) Beats Tivozanib+Nivolumab in Post-ICI mRCC PFS (No OS Gain)
Tivozanib (Tivo) is an oral, selective VEGFR tyrosine kinase inhibitor; TiNivo-2 (Phase 3; NCT04987203) tested ICI rechallenge by adding nivolumab (anti–PD-1) to tivozanib versus tivozanib alone in metastatic RCC…
NCT04987203
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.